NGM Biopharmaceuticals is a clinical-stage biotechnology company focused on developing transformative biologics addressing serious metabolic and liver diseases. The company’s science-driven platform emphasizes pathway-based discovery to develop novel drug candidates with strong therapeutic potential in areas such as NASH, fibrosis, obesity, and metabolic disorders.
Its collaborations with strategic partners support deep translational science, advanced clinical programs and scalable development. NGM’s pipeline reflects a balanced portfolio of proprietary and partnered assets, enabling the company to target complex diseases with high unmet need.
What Is NGM Biopharmaceuticals and What Does It Do?
NGM Biopharmaceuticals, founded in 2007 by Jin-Long Chen, is a San Francisco-based (United States) gastroenterology and metabolic-diseases biotechnology company developing first-in-class and best-in-class biologics. The company specializes in targeting fundamental metabolic and liver pathways through advanced protein-therapeutics engineering.
NGM employs 225 people, with expertise in research biology, protein engineering, translational science and clinical development.
The company focuses on tackling conditions such as NASH, bile-acid disorders, obesity and metabolic diseases through rigorous clinical investigation, precision targeting and a deep mechanistic understanding of disease biology.
How Much Funding Has NGM Biopharmaceuticals Raised?
1. Series D
- Amount Raised: $106M
- Date: March 25, 2015
- Lead Investors: Merck
- Motivation: Advance late-stage clinical development and expand R&D.
2. Series D (Tranche 1)
- Amount Raised: $57.5M
- Date: February 23, 2015
- Lead Investors: Prospect Venture Partners, TCG, Topspin, Tichenor Ventures
- Motivation: Strengthen clinical pipeline and early development programs.
3. Series C
- Amount Raised: $50M
- Date: July 18, 2013
- Lead Investors: Prospect Venture Partners, Rho Capital Partners
- Motivation: Support IND filings, safety studies and early clinical work.
Total Funding Raised: $359 Million
Latest Funding Date: March 25, 2015
Key Investors
1. Prospect Venture Partners
- Details: Biotech-focused VC backing clinical-stage therapeutic companies.
- Investment Focus Areas: Life sciences, biologics, therapeutics.
- Notable Investments: Illumina, Amgen (team level), Neuronetics, Topaz, multiple clinical biotechs.
2. Rho Capital Partners
- Details: Investment firm supporting life-science innovation.
- Investment Focus Areas: Biotechnology, therapeutics, diagnostics.
- Notable Investments: Unity Biotechnology, Reata Pharmaceuticals, Aerie Pharmaceuticals, Neuronetics, Neurana.
3. TCG (The Column Group)
- Details: Life-sciences investor focused on breakthrough therapeutics.
- Investment Focus Areas: Biologics, genetics, precision medicine.
- Notable Investments: BridgeBio, Revolution Medicines, Denali Therapeutics, eFFECTOR, Nura Bio.
Where Is NGM Biopharmaceuticals’s Headquarters?
NGM Biopharmaceuticals is headquartered in San Francisco, United States, with access to leading research institutions and biotech talent.
What’s Next for NGM Biopharmaceuticals?
The focus ahead includes progressing key clinical assets, expanding metabolic and liver-disease programs, strengthening commercial-readiness initiatives, and pursuing strategic collaborations for late-stage development.
Get Investor & Funding Insights with TexAu
TexAu helps sales and business teams uncover detailed fundraising information on companies like NGM Biopharmaceuticals. Use the platform to research investors, track funding rounds, and gather actionable insights to strengthen prospecting and business strategy.
Sign Up for Free on TexAu and start uncovering detailed funding insights that give your business a competitive edge.
